Scientific Program

Print
Thursday, September 11, 2014
15:00-16:30
 
 
15:00-15:05
 
 
 
 
15:05-15:15
15:15-15:25
15:25-15:35
15:35-15:40
15:40-15:45 15:45-15:50
15:50-15:55
15:55-16:05
 
16:05-16:30
 
Session 1

GENERAL/OPENING SESSION
Chairpersons: Giuseppe Saglio,
Italy; Eliezer Rachmilewitz, Israel

Accessibility and sustainability of new drugs (emphasizing the economical issues)
 
USA: Charles Schiffer, USA
Worldwide: Giuseppe Saglio, Italy
India: Hari Menon, India
Spain: Emili Montserrat, Spain
Germany: Rüdiger Hehlmann, Germany
Italy: Giuseppe Saglio, Italy
Israel: Eliezer Rachmilewitz, Israel
Turkey: Güray Saydam, Turkey
Panel Discussion
Charles Schiffer, USA
Giuseppe Saglio, Italy
Eliezer Rachmilewitz, Israel
Emili Montserrat, Spain
Rüdiger Hehlmann, Germany
 
16:30-17:00
Coffee Break
17:00-18:30
 
 
17:00-17:05
 
 
 
17:05-17:20
17:20-17:35
 
17:35-17:45
 
 
 
17:45-18:00
18:00-18:15
 
18:15-18:30
 
Session 2

IRON OVERLOAD
Chairpersons: Giuseppe Saglio, Italy; Selim Yavuz, Turkey
 
Is T2 MRI a reliable marker of pathological iron overload?
 
For: Sule Unal, Turkey
Against: Yoav Cabantchik, Israel
 
Discussion
 
Iron overload in MDS - is there a rationale for treatment?
 
For: Eliezer Rachmilewitz, Israel
Against: Charles Schiffer, USA
Discussion
 
18:30-19:30
Welcome Reception
Friday, September 12, 2014
08:00-09:30
 
 
08:00-08:05
 
 
 
 
08:05-08:20
08:20-08:35
 
08:35-08:45
 
 
 
08:45-09:15
 
09:15-09:30
Session 3

LYMPHOMA PART 1
Chairpersons: Emili Montserrat, Spain; Martin Dreyling, Germany
 
Should autologous transplantation be offered to all patients with Peripheral T Cell Lymphoma after induction therapy?

For: Maurizio Martelli, Italy
Against: Christian Gisselbrecht, France
 
Discussion
 
Will new monoclonal antibodies surpass and replace rituximab?
 
Pierluigi Zinzani, Italy
 
Discussion
09:30-10:00
Coffee Break
10:00-11:30
 
 
10:00-10:05
 
 
 
 
10:05-10:35
 
10:35-10:45
 
 
 
 
10:45-11:00
11:00-11:15
 
11:15-11:30
Session 4

MYELOPROLIFERATIVE DISEASE (MPN)
Chairpersons: Giuseppe Saglio, Italy; Suleyman Dincer, Turkey

Patients responding to Ruxolitinib should not be considered for allogenic transplantation?
 
Giovanni Barosi, Italy
Discussion
Is it time to start treating early stages of MPN and with what kind of treatment?
 
For: Tiziano Barbui, Italy
Against: Gunnar Birgegård, Sweden
 
Discussion
 
11:30-13:00
 
 
11:30-11:35
 
 
 
11:35-11:50
11:50-12:05
 
12:05-12:15
 
 
 
12:15-12:30
12:30-12:45
 
12:45-13:00
Session 5

CHRONIC MYELOID LEUKEMIA (CML)
Chairpersons: Rüdiger Hehlmann, Germany; Charles Schiffer, USA
 
Early (after 3 months) vs. later switch according to transcript levels

Early switch: Benjamin Hanfstein, Germany
Later switch: Fausto Castagnetti, Italy
 
Discussion

What is the best first line treatment for CML?

Imatinib: Güray Saydam, Turkey
2nd generation TKI: Giuseppe Saglio, Italy
 
Discussion
 
13:00-14:00
Lunch Break
14:00-15:30
 
 
14:00-14:05
 
 
 
14:05-14:20
14:20-14:35
 
14:35-14:45
 
 
 
14:45-15:00
15:00-15:15
 
14:15-15:30
Session 6
 
HAEMOGLOBINOPATHIES
Chairpersons: Griffin Rodgers, USA; Birol Güvenç, Turkey
 
Is there a role for stem cell transplantation in sickle cell anemia?

For: Miguel Abboud, Lebanon
Against: Salam Alkindi, Oman
 
Discussion
 
Is there a role for fetal hemoglobin inducers in haemoglobinopathies?

For: Yesim Aydinok, Turkey
Against: Aurelio Maggio, Italy
 
Discussion
 
15:30-17:00
 
 
15:30-15:35
 
 
 
15:35-15:50
15:50-16:05
 
16:05-16:15
 
 
 
16:15-16:30
16:30-16:45
 
16:45-17:00
Session 7

LYMPHOMA PART 2
Chairpersons: Christian Gisselbrecht, France; Mehmet Ali Özcan, Turkey

Is irradiation necessary for patients with early stage Hodgkin's disease?
 
For: Guido Parvis, Italy
Against: Davis Strauss, USA
 
Discussion

Is there an advantage of very aggressive treatment in Mantle Cell Lymphoma?
For: Martin Dreyling, Germany
Against: Umberto Vitolo, Italy
 
Discussion
 
17:00-17:30
Coffee Break
17:30-19:00 Satellite Symposium
 
Saturday , September 13, 2014
09:00-10:30
 
 
09:00-09:05
 
 
 
 
09:05-09:20
09:20-09:35
 
09:35-09:45
 
 
 
 
09:45-10:00
10:00-10:15
 
10:15-10:30
Session 8

MYELODYSPLASTIC SYNDROME (MDS)
Chairpersons: Mehmet Ali Özcan, Turkey
 
Should patients with RAEB or oligoblastic AML receive induction chemotherapy prior to allogeneic transplantation?
 
For: Valeria Santini, Italy
Against: Daniella Cilloni, Italy
 
Discussion
BONE MARROW TRANSPLANTATION
Is cord blood better than haploidentical donor for patients without an HLA matched donor?
 
For: Arnon Nagler, Israel
Against: Francesco Frassoni, Italy
 
Discussion
 
10:30-11:00
Coffee Break
11:00-12:30
 
 
11:00-11:05
 
 
 
 
11:05-11:20
11:20-11:35
 
11:35-11:45
 
 
 
11:45-12:00
12:00-12:15
 
12:15-12:30
 
Session 9

MULTIPLE MYELOMA (MM)
Chairpersons: Umberto Vitolo, Italy; Osman Ilhan, Turkey

Should patients with "high risk” myeloma be considered for allogeneic transplant?

For: Bart Barlogie, USA
Against: Mutlu Arat, Turkey
 
Discussion

Is there an indication to treat high risk MGUS?

For: Meral Beksac, Turkey
Against: Joan Bladé, Spain
 
Discussion
12:30-14:00
 
 
12:30-12:35
 
 
 
 
12:35-12:50
12:50-13:05
 
13:05-13:15
 
 
 
 
13:15-13:30
13:30-13:45
 
13:45-14:00
Session 10

COAGULATION DISORDERS
Chairpersons: Tiziano Barbui, Italy; Suleyman Dincer, Turkey
 
Should low molecular weight heparin be used routinely in pregnancy complications?

For: Dorit Blickstein, Israel
Against: Jean Christophe Gris, France
 
Discussion
 
Should Thrombophilia workup be performed routinely in patients with unprovoked Venous Thrombo-Embolic events?

For: Papadakis Emmanouil, Greece
Against: Benjamin Brenner, Israel
 
Discussion
 
14:00-15:00
Lunch Break
15:00-16:30
 
 
15:00-15:05
 
 
 
 
15:05-15:20
15:20-15:35
 
15:35-15:45
 
 
 
15:45-16:00
16:00-16:15
 
16:15-16:30
 
Session 11

ACCUTE LEUKEMIA (AML, ALL)
Chairpersons: Robin Foá, Italy; Mehmet Yilmaz, Turkey

Should all adults fit patients with ALL undergo bone marrow transplantation in first CR?

For: Jose Ribera, Spain
Againts: Dieter Hoelzer, Germany
 
Discussion

Should molecular characterization of AML help guide therapy?

For: Lars Bullinger, Germany
Against: Alan Burnett, UK
 
Discussion
 
16:30-16:45
Coffee Break
16:45-18:15
 
 
16:45-16:50
 
 
 
16:50-17:05 17:05-17:20
 
17:20-17:30 
 
 
 
17:30-17:45
17:45-18:00
 
18:00-18:15
Session 12

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Chairperson: Mustafa Çetiner, Turkey; Robin Foá, Italy

Should minimal residual disease be a therapy endpoint?

For: Matthias Ritgen, Germany
Against: Stephen Mulligan, Australia
 
Discussion

Should novel mutations be considered prognostic factors in CLL?

For: Gianluca Gaidano, Italy
Against: Emili Montserrat, Spain
 
Discussion
 
18:15-18:30
Closing Ceremony